The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Here's a recap of the week’s most important stories.

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk (NYSE:NVO) said CEO Lars Fruergaard Jrgensen will step down after eight years at the helm, following a sharp ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Shares of Novo Nordisk (NYSE: NVO) fell 3% today following the announcement that CEO Lars Fruergaard Jørgensen will step down ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Novo Nordisk's CEO Lars Fruergaard Jorgensen was ousted as the company struggles to maintain its dominance in the highly ...

However, investors are advised not to jump to conclusions regarding acquiring/retaining the stock ... to date, Novo Nordisk shares have plunged 23.1% compared with the industry’s decline of ...